|Mr. David Ian Johnson||Exec. Chairman||418.75k||N/A||1958|
|Dr. Joseph Edward Tucker Ph.D.||CEO & Director||474.82k||N/A||1969|
|Mr. Avani V. Kanubaddi||Pres & COO||447.07k||N/A||1973|
|Mr. Carter J. Ward CPA, CSCP||Chief Financial Officer||N/A||N/A||1964|
|Dr. Peter J. Facchini Ph.D.||Chief Innovation Officer||303.52k||N/A||1964|
|Dr. Ibrahim Dagher M.D.||Chief Medical Officer||N/A||N/A||1969|
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Enveric Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.